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(100 mg p.o., days 1-7) ). Seven years later, the patient remains in complete remission.
The evidence presented herein suggests that in our series T-LGL leukemia grew concomitantly with CBLPDs. Documentation of the clonal T-LGL and B cell entities was based upon morphologic criteria (apart from case No. 8 in whom PB lymphocytes lacked typical LGL morphology; however, occasionally, clonally expanded lymphocytes with a characteristic CD3 + CD57 + phenotype may not have LGL morphology on PB smear 1 ), immunophenotypic analysis and genotypic profile. Their distribution in the tissues examined was immunophenotypically and genotypically discriminate.
The low frequency both of the CBLPDs identified in our cases and T-LGL leukemia suggests that their simultaneous occurrence might not be fortuitous. The possibility that the CTLGLPs detected in our patients might react to the monoclonal B cell populations is not very likely: this is supported by the findings in case No. 8, where the spleen and liver were massively infiltrated by neoplastic T-LGLs. Furthermore, it can not be definitely excluded that the CBLPDs identified might share a common malignant precursor with T-LGL leukemias. Another, in our view more plausible, explanation might be that CBLPDs emerged secondarily due to B cell dysfunction in the setting of T-LGL leukemia; 1, 5, 6 in most cases, unlike LGLs from healthy individuals, abnormally expanded T-LGL leukemia cells, despite being CD8
+ , are incapable of suppressing immunoglobulin synthesis in vivo. 1 Thus, uncontrolled Ig production with autoantibody formation could eventually lead to the development of clonal B cell disorders, as in the few cases in the literature and in our cases as well. 1, 3, 4 However, it should not be overlooked that T-LGLs with cytotoxic/suppressor phenotype might function as contrasuppressor T cells.
In conclusion, our cases support the notion that T-LGL leukemia can coexist with B cell dysfunction and/or B cell lymphoproliferative diseases, including MGUS and multiple myeloma; the exact pathophysiologic mechanism awaits further clarification. Furthermore, these results emphasize the value of a combined immunophenotypic and molecular analysis of the PB as part of the evaluation of CBLPDs in order to detect CTLGLP, which may pass unnoticed on morphologic examination. Finally, it is not unreasonable to argue that while investigating limited BM SLIs the hemopathologist should be alert for the possibility of coexisting B and T lymphoproliferations. 2 Are Pgp and glucosylceramide synthase coregulated, and how do Pgp modulators influence ceramide glycosylation? Another example of co-operativity of drug resistance mechanisms is the attenuation of mitochondrial transmembrane potential in the adriamycin-selected Pgp-positive K562 cell variant; this phenomenon was interpreted as a mechanism of utilization of reactive oxygen species (ROS) (Ref. 7 and references therein). The concerted action of Pgp with other mechanisms may provide an additional advantage for the cell to survive the cytotoxic insult. Can inhibition of Pgp disrupt the whole hierarchy of determinants of resistance?
P-glycoprotein as a therapeutic target: good news
These considerations imply that Pgp is a key factor in acquisition of MDR. This statement is not underscored by the fact that, in drugselected cells, other mechanisms may become equally important (or even predominant) in particular resistant phenotype. Indeed, Pgpmediated MDR can emerge as part of general response after a shortterm exposure of cells to a variety of stimuli including chemotherapeutics. This effect was observed in an array of cultured leukemic lines, H9, K562 and KG1, and patients' tumours (reviewed in Ref. 7) . Because the MDR1/Pgp gene activation is rapid and sustained, Pgp should be among the factors that emerge early during the development of pleiotropic resistance. However, temporal order of events does not necessarily point to their causative link, and such a link between acquisition of Pgp-mediated MDR and establishment of other resistance mechanisms remains to be proven. Nevertheless, Pgp inhibition seems a prerequisite for circumventing complex-resistant phenotypes.
Second, what are the mechanism(s) of cytotoxicity of Pgp blockers for MDR cells? Malignant cells may possess defects in death machinery even prior to drug treatment (intrinsic resistance). Down-regulation of certain death pathways in the course of prolonged drug selection would not be surprising because this might ensure survival. In the long run, the selection procedure would yield a population in which the balance of pro-and anti-apoptotic machineries is shifted to favour cell viability. However, preferential susceptibility of MDR cells to certain agents (including PSC 833 and inhibitors of glucosylceramide synthase) implies that drug-selected cells 'pay the price' for their multifactorial resistance with an increased sensitivity to certain stimuli. It remains to be elucidated whether different Pgp blockers are indeed selectively toxic against MDR cells as compared to their nonselected counterparts. Does such selectivity presume the 'unique' patterns of functional death pathways in MDR cells? If that is the case, triggering these pathways would allow for targeted elimination of resistant variants.
The plasma membrane seems an attractive target for killing MDR cells because Pgp does not protect from the loss of the membrane integrity. 8 This effect can be achieved via generation of membranotropic intracellular metabolites such as ROS. The toxicity of ROS is not confined to the break of biological membranes (necrosis); oxygen burst-induced damage of macromolecules can trigger apoptotic cascades. This complex mode of cytotoxicity may be efficient in cells otherwise resistant to many poisons including Pgp-transported chemotherapeutics. It is worth studying whether ROS are especially toxic for MDR cells as compared to their parental variants.
Finally, is the therapeutic effect restricted to one particular tumour model and a certain Pgp blocker? Definitely, the analysis of a broad panel of malignant cell lines of different origin is needed to assess the role of Pgp as a general target for antitumour treatment. Furthermore, it is important to demonstrate whether Pgp modulators not only postpone the engraftment of MDR cells but are active against a preestablished tumour. Given that drug-resistant phenotypes are multifactorial, it would be important to evaluate the effects of Pgp inhibitors in cells with Pgp-unrelated resistance.
Whatever the mechanisms, at least two considerations seem straightforward: (1) up-regulation of defense systems is accompanied by a switch of functional death pathways, thereby making the MDR cell an entity with peculiar metabolic profile; (2) Pgp modulators are the group of pharmacological agents promising for selective elimination of MDR cells. The results of Lehne et al 1 prove the principle for a mechanism-based, Pgp-targeted therapy for circumvention of MDR in cancer.
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